Drug Type Bispecific antibody |
Synonyms DuoHexaBody-CD37, HexaBody-CD37, ivicentamab + [2] |
Target |
Mechanism CD37 modulators(Leukocyte antigen CD37 modulators) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic Lymphocytic Leukemia | Phase 2 | DK | 13 Mar 2020 | |
Chronic Lymphocytic Leukemia | Phase 2 | US | 13 Mar 2020 | |
Chronic Lymphocytic Leukemia | Phase 2 | BE | 13 Mar 2020 | |
Chronic Lymphocytic Leukemia | Phase 2 | FR | 13 Mar 2020 | |
Chronic Lymphocytic Leukemia | Phase 2 | ES | 13 Mar 2020 | |
Chronic Lymphocytic Leukemia | Phase 2 | NL | 13 Mar 2020 | |
Small Lymphocytic Lymphoma | Phase 2 | FR | 13 Mar 2020 | |
Small Lymphocytic Lymphoma | Phase 2 | BE | 13 Mar 2020 | |
Small Lymphocytic Lymphoma | Phase 2 | DK | 13 Mar 2020 | |
Small Lymphocytic Lymphoma | Discovery | US | 13 Mar 2020 |
Phase 1/2 | 46 | (Part 1: GEN3009 Dose Level A in S1) | ydnenrzpeg(ftfbtceltq) = uglkhvgkzs pbbclvtfsc (crkwwpowyh, uivijdcwhm - ayundwwiqc) View more | - | 13 Aug 2024 | ||
(Part 1: GEN3009 Dose Level B in S1) | ydnenrzpeg(ftfbtceltq) = vzmmtoeltp pbbclvtfsc (crkwwpowyh, qvuvehtcou - kiazokgrzu) View more |